Immunotherapy for deficient mismatch repair (dMMR) pancreatic ductal adenocarcinoma

被引：2
作者：
Ebia, Matthew I. [1 ]
Hitchins, Megan P. [2 ]
Hendifar, Andrew E. [1 ,3 ,4 ]
机构：
[1] Cedars Sinai Med Ctr, Dept Med, Div Hematol & Oncol, Los Angeles, CA USA
[2] Cedars Sinai Med Ctr, Dept Biomed Sci, Los Angeles, CA USA
[3] Cedars Sinai Samuel Oschin Comprehens Canc Inst, Los Angeles, CA USA
[4] Cedars Sinai Med Ctr, Dept Med, Div Hematol & Oncol, 8700 Beverly Blvd,Suite 1042AC, Los Angeles, CA 90048 USA
来源：
JOURNAL OF GASTROINTESTINAL ONCOLOGY | 2023年 / 14卷 / 02期
关键词：
Pancreatic ductal adenocarcinoma (PDAC); DNA deficient mismatch repair (DNA dMMR); microsatellite instability (MSI); Lynch syndrome; immunotherapy; CANCER;
D O I：
10.21037/jgo-23-12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1175 / 1177
页数：3
相关论文
共 50 条
  • [21] Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma
    Fan, Jia-qiao
    Wang, Meng-Fei
    Chen, Hai-Long
    Shang, Dong
    Das, Jugal K.
    Song, Jianxun
    MOLECULAR CANCER, 2020, 19 (01)
  • [22] Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects
    LiKe-Yu
    YuanJia-Long
    TraftonDiego
    WangJian-Xin
    NiuNan
    YuanChun-Hui
    LiuXu-Bao
    ZhengLei
    慢性疾病与转化医学（英文）, 2020, (01) : 6 - 17
  • [23] Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate
    Schweizer, Michael T.
    Cheng, Heather H.
    Tretiakova, Maria S.
    Vakar-Lopez, Funda
    Klemfuss, Nola
    Konnick, Eric Q.
    Mostaghel, Elahe A.
    Nelson, Peter S.
    Yu, Evan Y.
    Montgomery, Bruce
    True, Lawrence D.
    Pritchard, Colin C.
    ONCOTARGET, 2016, 7 (50) : 82504 - 82510
  • [24] Immune escape and resistance to immunotherapy in mismatch repair deficient tumors
    Mestrallet, Guillaume
    Brown, Matthew
    Bozkus, Cansu Cimen
    Bhardwaj, Nina
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [25] Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer
    Dionisia Quiroga
    H. Kim Lyerly
    Michael A. Morse
    Current Treatment Options in Oncology, 2016, 17
  • [26] Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer
    Thomas, Jane
    Leal, Alexis
    Overman, Michael J.
    CLINICAL COLORECTAL CANCER, 2020, 19 (02) : 73 - 81
  • [27] The immune escape signature predicts the prognosis and immunotherapy sensitivity for pancreatic ductal adenocarcinoma
    Lu, Hao
    Zheng, Li-Yan
    Wu, Ling-Yan
    Chen, Jun
    Xu, Na
    Mi, Sui-Cai
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [28] Pancreatic ductal adenocarcinoma harboring microsatellite instability / DNA mismatch repair deficiency. Towards personalized medicine
    Lupinacci, Renato M.
    Bachet, Jean-Baptiste
    Andre, Thierry
    Duval, Alex
    Svrcek, Magali
    SURGICAL ONCOLOGY-OXFORD, 2019, 28 : 121 - 127
  • [29] Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy
    Panagiotis Sarantis
    Evangelos Koustas
    Adriana Papadimitropoulou
    Athanasios G Papavassiliou
    Michalis V Karamouzis
    World Journal of Gastrointestinal Oncology, 2020, 12 (02) : 173 - 181
  • [30] Macrophage-based immunotherapy for the treatment of pancreatic ductal adenocarcinoma
    Beatty, Gregory L.
    ONCOIMMUNOLOGY, 2013, 2 (12)
12345